Nepsis Capital Management Inc. increased its stake in shares of Medtronic PLC (NYSE:MDT) by 3.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,137 shares of the medical technology company’s stock after buying an additional 2,231 shares during the period. Medtronic PLC comprises approximately 2.9% of Nepsis Capital Management Inc.’s holdings, making the stock its 19th largest position. Nepsis Capital Management Inc.’s holdings in Medtronic PLC were worth $5,369,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in MDT. Hudock Capital Group LLC raised its stake in Medtronic PLC by 0.5% in the second quarter. Hudock Capital Group LLC now owns 2,150 shares of the medical technology company’s stock valued at $186,000 after buying an additional 10 shares in the last quarter. Moody National Bank Trust Division raised its stake in Medtronic PLC by 0.5% in the second quarter. Moody National Bank Trust Division now owns 6,953 shares of the medical technology company’s stock valued at $603,000 after buying an additional 35 shares in the last quarter. Telemus Capital LLC raised its stake in Medtronic PLC by 1.4% in the third quarter. Telemus Capital LLC now owns 2,502 shares of the medical technology company’s stock valued at $216,000 after buying an additional 35 shares in the last quarter. Kistler Tiffany Companies LLC raised its stake in Medtronic PLC by 2.1% in the second quarter. Kistler Tiffany Companies LLC now owns 1,776 shares of the medical technology company’s stock valued at $154,000 after buying an additional 36 shares in the last quarter. Finally, Trust Co. of Toledo NA OH raised its stake in Medtronic PLC by 0.4% in the second quarter. Trust Co. of Toledo NA OH now owns 11,046 shares of the medical technology company’s stock valued at $958,000 after buying an additional 40 shares in the last quarter. 81.25% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Medtronic PLC (NYSE:MDT)

Medtronic PLC (NYSE:MDT) traded down 0.34% during mid-day trading on Friday, hitting $75.52. The stock had a trading volume of 3,045,998 shares. Medtronic PLC has a 52-week low of $71.03 and a 52-week high of $89.27. The stock has a market cap of $104.36 billion, a P/E ratio of 29.39 and a beta of 1.01. The firm has a 50-day moving average of $81.84 and a 200-day moving average of $84.68.

Medtronic PLC (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 22nd. The medical technology company reported $1.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.11 by $0.01. The firm had revenue of $7.35 billion for the quarter, compared to analyst estimates of $7.46 billion. Medtronic PLC had a net margin of 14.63% and a return on equity of 12.36%. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.03 EPS. On average, analysts forecast that Medtronic PLC will post $4.63 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Nepsis Capital Management Inc. Buys 2,231 Shares of Medtronic PLC (MDT)” was first reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/27/nepsis-capital-management-inc-buys-2231-shares-of-medtronic-plc-mdt.html.

A number of equities analysts have recently weighed in on the company. Barclays PLC dropped their price objective on Medtronic PLC from $93.00 to $85.00 and set an “overweight” rating for the company in a research note on Wednesday. Oppenheimer Holdings Inc. dropped their price objective on Medtronic PLC from $94.00 to $84.00 and set an “outperform” rating for the company in a research note on Wednesday. Vetr lowered Medtronic PLC from a “strong-buy” rating to a “buy” rating and set a $91.28 price objective for the company. in a research note on Monday, November 21st. Needham & Company LLC upped their price objective on Medtronic PLC from $93.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, August 25th. Finally, Stifel Nicolaus dropped their price objective on Medtronic PLC from $91.00 to $81.00 and set a “hold” rating for the company in a research note on Wednesday. Seven analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $88.47.

In other news, VP Richard Kuntz sold 25,199 shares of Medtronic PLC stock in a transaction that occurred on Monday, September 26th. The shares were sold at an average price of $86.67, for a total transaction of $2,183,997.33. Following the sale, the vice president now owns 149,425 shares of the company’s stock, valued at approximately $12,950,664.75. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Bryan C. Hanson sold 15,000 shares of Medtronic PLC stock in a transaction that occurred on Monday, August 29th. The shares were sold at an average price of $87.00, for a total transaction of $1,305,000.00. Following the sale, the executive vice president now directly owns 168,192 shares in the company, valued at approximately $14,632,704. The disclosure for this sale can be found here. Insiders own 0.25% of the company’s stock.

About Medtronic PLC

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

5 Day Chart for NYSE:MDT

Receive News & Stock Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related stocks with our FREE daily email newsletter.